查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年兽用镇痛药物的全球市场
市场调查报告书
商品编码
1166510

2022-2029 年兽用镇痛药物的全球市场

Global Veterinary Pain Management Drugs Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

2021 年兽用镇痛药物的全球市场规模预计将达到 12.217 亿美元，在预测期内（2022-2029 年）以 5.6% 的复合年增长率增长。

兽医疼痛管理是指为伴侣动物和农场动物提供骨关节炎、术后疼痛和癌症等疾病的预防、诊断和治疗的医疗服务。

市场动态

全球兽医疼痛管理市场的增长是由特定因素驱动的，例如动物疼痛和炎症性疾病患病率上升、动物保健力度加大以及伴侣动物数量增加等因素驱动。

政府对动物保健的举措不断增加，预计将在预测期内推动全球兽医镇痛药物市场。

2019 年 11 月，世界小动物兽医协会 (WSAVA) 的全球疼痛委员会 (GPC) 宣布，其目标是建立疼痛管理领域的关键意见领袖 (KOL) 全球网络。我们启动了一个名为“教学”并正在开展雄心勃勃的活动，以在该地区传播和传播知识。

2020 年 3 月，10% 酮芬的製造商 Seba Animal Health 发布了“向疼痛挥手告别”，强调了缓解疼痛对跛脚牛的积极影响及其在改善恢復时间和性能方面的作用。”推出了活动。 该运动揭示了注射非甾体抗炎药（抗炎镇痛药）与有效修蹄和阻滞治疗跛足的协同作用（不仅仅是相加）。它是根据研究结果发起的。 这一发现是第二项表明奶牛场经营者在过去十年中越来越意识到他们需要缓解疼痛的研究，其中 52% 愿意支付额外费用（高于 2006 年的 36%）。与结果一起发布。

分销渠道的变化可能会阻碍市场增长

伴侣动物主人通常直接从兽医那里购买兽药。 伴侣动物主人已经改变了他们的购买模式，将他们的注意力转移到基于互联网的零售商、零售店和其他销售点渠道。 当确定人类药物更便宜时，此类变化导致伴侣健康所有者选择人类药物而不是动物药物。

此外，兽医等主要客户的整合会对配套保健产品的定价产生负面影响。 此外，低价仿製药及其增加的使用量可能会阻碍市场潜力。 监管机构的监管会对止痛药的销售产生不利影响。 伴随医疗保健成本的上升和对动物试验的严格监管可能会进一步阻碍市场。

此外，由于运输网络不完善、缺乏冷藏设施以及缺乏用于健康检查的化验实验室网络，可能难以将药品和疫苗运送到需要的地方。 采购模式的变化、仿製药使用的增加、低价人用药物的次级限制以及监管限制是可能显着抑制市场增长的一些关键因素。

COVID-19 影响分析

COVID-19 疫情正在影响全球所有行业，包括动物止痛药。 建议宠物父母与宠物保持安全距离，以保持卫生并降低感染风险。 此外，畜牧业也受到影响。 肉类、牛奶和鸡蛋等动物产品越来越难以销售。 对反刍动物的季节性过境点实施了限制。 例如，2020 年 4 月，粮食及农业组织在 COVID-19 大流行期间宣布了有关畜牧生产和动物产品供应链的新政策。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按药物划分的市场细分
  • 按给药途径细分的市场
  • 按动物分类的市场细分
  • 按应用划分的市场细分
  • 按分销渠道细分的市场
  • 按地区划分的市场细分

第四章市场动态

  • 市场影响因素
  • 司机
    • 动物中疼痛和炎症性疾病的流行率增加
    • 动物保健倡议的增加
    • 伴侣动物数量增加
  • 约束因素
    • 与药物有关的副作用
    • 分销渠道的变化
  • 商机
  • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 监管分析
  • 定价分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按药物类型分类

  • 非甾体抗炎药
    • 美洛昔康
    • 德拉昔布
    • 卡洛芬
    • 依托度酸
    • 非罗考昔
    • 其他
  • 阿片类药物
    • 吗啡
    • 可待因
    • 芬太尼
    • 丁丙诺啡
    • 其他
  • 局部麻醉剂
    • 利多卡因
    • 布比卡因
    • 甲□卡因
    • 其他
  • α2激动剂
    • 美托咪定
    • 甲苯塞秦
    • 罗米非丁
    • 其他
  • 缓解疾病的骨关节炎治疗剂 (DMOAD)
    • 其他

第8章给药途径

  • 口语
  • 肠外
  • 局部管理

第9章动物

  • 伴侣动物
    • 狗
    • 猫
    • 马
    • 其他动物（伴侣动物）
  • 牲畜
    • 奶牛
    • 猪
    • 其他畜产品

第 10 章应用

  • 术后疼痛
  • 关节痛
    • 骨关节炎
    • 肌肉骨骼疾病
  • 癌症
  • 其他

第 11 章分销渠道

  • 兽医医院和诊所
  • 零售药房
  • 在线药店

第12章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第13章竞争格局

  • 竞争场景
  • 製造商采用的主要策略
  • 市场分析/市场份额分析
  • 产品基准

第14章公司简介

  • Dechra Pharmaceuticals
    • 公司简介
    • 程序组合和描述
    • 主要亮点
    • 财务摘要
  • Zoetis
  • Elanco
  • Boehringer Ingelheim
  • Vetoquinol S.A.
  • Ceva Sante Animale S.A.
  • Bayer AG
  • Merck Animal Health
  • Norbrook Laboratories
  • Chanelle Pharma
  • Virbac
  • Assisi Animal Health

第15章 数据

简介目录
Product Code: DMVH539

Market Overview

The global veterinary pain management drugs market size was valued at US$ 1221.7 million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.6% during the forecast period (2022-2029).

Veterinary Pain Management Drugs refers to the medical services for the prevention, diagnosis, and treatment of diseases like Osteoarthritis, Postoperative pain, and Cancer in companion and livestock animals.

Market Dynamics

The global veterinary pain management drugs market growth is driven by the certain factors such as the rising prevalence of painful and inflammatory diseases in animals, increasing initiatives towards animal healthcare and increasing number of companion animal ownership.

The increasing government initiative towards animal healthcare, is expected to drive the global veterinary pain management drugs market during the forecast period

In November 2019, the Global Pain Council (GPC) of the World Small Animal Veterinary Association (WSAVA) has launched a program called 'Teach the Teachers,' which aims to create a global network of key opinion leaders (KOLs) - 'teachers' - in pain management, who are motivated to propagate and disseminate their knowledge within their regions.

In March 2020, Ceva Animal Health, the manufacturer of Ketofen 10%, has launched a 'Wave Goodbye to Pain' campaign to highlight the positive impact of pain relief on lame cattle and the role it can play in improving recovery time and results. The initiative was launched following a study by Nottingham University which revealed that NSAIDs (anti-inflammatory and pain-relieving injections) have a synergistic (greater than simply additive) effect when given alongside effective hoof trimming and blocking to treat lameness. The findings have emerged alongside a second study showing that over the last 10 years, farmers are increasingly aware of the need for pain relief and 52% are happy to pay the extra costs involved (up from 36% in 2006).

Changes in distribution channel are likely to hinder the market growth

Generally, companion animal owners purchase their animal health products directly from veterinarians. Companion animal owners has changed their purchase pattern and shifted the focus towards internet-based retailers, retail stores, or other over-the-counter distribution channels. This shift is leading the companion health owners to opt for substitute human health products for animal health products if human health products are deemed to be lower-cost alternatives.

Moreover, consolidation of primary customers such as veterinarians might adversely affect price of companion healthcare products. Further, low-cost generic product subtitles and their increased usage might hamper the market potential. Restrictions by regulatory bodies might have a negative impact on the sales of pain relief drugs. Increasing costs of companion healthcare and increasing regulations on animal testing might further hamper the market.

Moreover, lack of infrastructure may also make it difficult to transport medicines and vaccines to where they are required because of poor transport links, lack of refrigeration, and networks of laboratories for conducting health tests. Change in purchase patterns, increased generic drugs, low-cost human drug sublimities, and regulatory restriction are key factors which might restrain the market growth significantly.

COVID-19 Impact Analysis

The COVID-19 outbreak has impacted all global industries, including veterinary pain medicine. Pet parents are advised to keep a safe distance from their pets to maintain hygiene and reduce the risk of contamination. Moreover, the impact has been seen in the livestock sector. Moving animal products, such as meat, milk, and eggs, has been trouble moving to markets. The restriction has been implemented on the seasonal border crossing with ruminants. For example, in April 2020, the Food Agriculture Organization published a new policy regarding the production of livestock and the supply chain of livestock products during the COVID-19 pandemic.

Segment Analysis

The non-steroidal anti-inflammatory drugs (NSAIDs) segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Non-steroidal anti-inflammatory drugs are one of the most commonly used and most effective drug in the treatment of pain due to arthritis or after surgery in dogs and cats. Rimadyl, Metacam, Dermaxx, Etogesic, among others comes under this class of drugs. NSAIDS act by inhibiting inflammatory substances called prostaglandins (PGEs), which cause pain, inflammation, and fever. Hence they are called 'anti-inflammatory' but their main purpose is pain control (inflammation is how pain starts). These drugs are readily available, relatively long-acting, and generally inexpensive. They can also be given at home after an animal has been released from the hospital. For these reasons, they have long been used for pain relief. Veterinarians may prescribe NSAIDs as one part of the total plan for pain relief, provided the animal does not have kidney, liver, blood clotting, or stomach problems.

However, some side effects can occur, with the most common being gastrointestinal (GI) disturbance (symptoms include vomiting, diarrhea, bloody or dark colored feces) from minor GI-ulcers. There is also risk of acute liver and/or kidney failure with all NSAIDs.

Geographical Analysis

North America region holds the largest market share of the global veterinary pain management drugs market

North America accounted for the largest share of the veterinary pain management market. Rise in the number of veterinarians across the world is believed spearhead current and future market growth of veterinary pain management drugs during the forecast period. For instance, according to the 2019-2020 National Pet Owners Survey, conducted by the American Pet Products Association (APPA), around 67% of the country's households, or about 84.9 million families, own a pet. In addition, highly developed and well-established animal healthcare facilities is further fueling the growth.

Rising collective efforts by key players to improve their product portfolio and to ensure high-quality standards are projected to boost the regional demand. For instance, in May 2017, Norbrook launched chewable Carprieve tablets for dogs in a probe to expand its product portfolio.

In 2020, the United States Food & Drug Administration approved Cronus Pharma Specialties' Carprofen Chewable Tablets (generic version of Rimadyl-Zoetis) for dogs. This nonsteroidal anti-inflammatory drug (NSAID) has been proven safe and effective in relieving pain and inflammation associated with osteoarthritis. Also, it helps control postoperative pain associated with soft tissue and orthopedic surgeries.

Competitive Landscape

The veterinary pain management drugs market is highly competitive and consists of a large number of players.

Some of the major players in the global veterinary pain management drugs market are Dechra Pharmaceuticals, Zoetis, Elanco, Boehringer Ingelheim, Vetoquinol S.A., Ceva Sante Animale S.A., Bayer AG, Merck Animal Health, Norbrook Laboratories, Chanelle Pharma, Virbac, among others. The key players are adopting strategies such as mergers and acquisitions, partnerships, and regional expansion to stand out as strong competitors in the market. New product launches along with increased focus on R&D are other ways the leading players improve their market presence.

For instance, In April 2020, The UK Competition and Markets Authority or CMA Monday has launched a merger inquiry into Dechra Pharmaceuticals PLC's (DPH.L) anticipated acquisition of the Osurnia business of Elanco Animal Health Inc. (ELAN).

Key Companies to Watch

Zoetis Inc

Overview: Zoetis Inc. is a U.S. based animal health company involved in the production of medicine, vaccines, diagnostic products and other veterinary solutions. The company is considered as the global leader in veterinary vaccines market. The company is operating under three reportable segments - Livestock, Companion Animal and Contract manufacturing & human health. Zoetis's Livestock business is responsible for the development, production and distribution of vaccines, anti-infective, paraciticides and medicated feed additives.

Product Portfolio: SIMBADOL (buprenorphine injection) offers continuous 24-hour surgical pain control for cats - even through the night.

The global veterinary pain management drugs market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Drugs
  • 3.2. Market Snippet by Route of Administration
  • 3.3. Market Snippet by Animal
  • 3.4. Market Snippet by Application
  • 3.5. Market Snippet by Distribution Channel
  • 3.6. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Rising Prevalence of Painful and Inflammatory Diseases in Animals
    • 4.2.2. Increasing Initiatives towards Animal Healthcare
    • 4.2.3. Increasing number of companion animal ownership
  • 4.3. Restraints
    • 4.3.1. Side Effects Associated with Drugs
    • 4.3.2. Changes in Distribution Channel
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
    • 7.1.2. Market Attractiveness Index, By Drug Type Segment
  • 7.2. NSAIDS*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
    • 7.2.3. Meloxicam
    • 7.2.4. Deracoxib
    • 7.2.5. Carprofen
    • 7.2.6. Etodolac
    • 7.2.7. Firocoxib
    • 7.2.8. Others
  • 7.3. Opioids
    • 7.3.1. Morphine
    • 7.3.2. Codeine
    • 7.3.3. Fentanyl
    • 7.3.4. Buprenorphine
    • 7.3.5. Others
  • 7.4. Local Anesthetics
    • 7.4.1. Lidocaine
    • 7.4.2. Bupivacaine
    • 7.4.3. Mepivacaine
    • 7.4.4. Others
  • 7.5. Alpha-2 Agonists
    • 7.5.1. Medetomidine
    • 7.5.2. Xylazine
    • 7.5.3. Romifidine
    • 7.5.4. Others
  • 7.6. Disease Modified Osteoarthritis Drugs (DMOAD)
    • 7.6.1. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
    • 8.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
  • 8.3. Parenteral
  • 8.4. Topical

9. By Animal

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Segment
    • 9.1.2. Market Attractiveness Index, By Animal Segment
  • 9.2. Companion Animal*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
    • 9.2.3. Dogs
    • 9.2.4. Cats
    • 9.2.5. Horses
    • 9.2.6. Other Companion Animals
  • 9.3. Livestock
    • 9.3.1. Cattle
    • 9.3.2. Swine
    • 9.3.3. Other Livestock Animals

10. By Application

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 10.1.2. Market Attractiveness Index, By Application Segment
  • 10.2. Postoperative Pain*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
  • 10.3. Joint Pain
    • 10.3.1. Osteoarthritis
    • 10.3.2. Musculoskeletal Disorders
  • 10.4. Cancer
  • 10.5. Other

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
    • 11.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 11.2. Veterinary Hospitals & Clinics*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, Y-o-Y Growth Analysis (%)
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. The Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Key Strategies adopted by Manufacturers
  • 13.3. Market Positioning/Share Analysis
  • 13.4. Product Benchmarking

14. Company Profiles

  • 14.1. Dechra Pharmaceuticals*
    • 14.1.1. Company overview
    • 14.1.2. Procedure portfolio and description
    • 14.1.3. Key highlights
    • 14.1.4. Financial overview
  • 14.2. Zoetis
  • 14.3. Elanco
  • 14.4. Boehringer Ingelheim
  • 14.5. Vetoquinol S.A.
  • 14.6. Ceva Sante Animale S.A.
  • 14.7. Bayer AG
  • 14.8. Merck Animal Health
  • 14.9. Norbrook Laboratories
  • 14.10. Chanelle Pharma
  • 14.11. Virbac
  • 14.12. Assisi Animal Health

15. DataM Intelligence

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us